NewLink Genetics to Host Its First Quarter 2018 Financial Results Conference Call on May 3, 2018

by NASDAQ Market News April 20, 2018

NASDAQ Market News
Click here to email author

Helsinn Group announces the FDA approval of the IV formulation of AKYNZEO® (fosnetupitant/ palonosetron) in the United States

Data from Multiple Celldex Programs Presented at American Association for Cancer Research (AACR) Annual Meeting 2018

Ads